DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.
Frequently asked questions
When was CorMedix Inc.’s public offering?
On March 25, 2010, CorMedix announced the pricing of its initial public offering of 1,925,000 units at $6.50 per unit. Each unit consisted of two shares of CorMedix common stock and a warrant to purchase one share of common stock at a price of $3.4375.
What is CorMedix Inc.’s common stock ticker symbol and what exchange is CorMedix traded on?
CorMedix’s common stock is traded on the Nasdaq Global Market under the ticker symbol CRMD.
What is the CUSIP number for CorMedix Inc.’s common stock?
The CUSIP number for CorMedix’s common stock is 21900C308.
How can I purchase shares of CorMedix Inc. common stock?
At this time, CorMedix does not have a direct purchase program. CorMedix stock may be purchased through a broker or a financial institution that deals in securities.
Who is CorMedix Inc.’s stock transfer agent?
The transfer agent and registrar for CorMedix’s common stock is VStock Transfer, LLC. The contact information for VStock Transfer is 18 Lafayette Place, Woodmere, New York 11598, 212-828-8436.
When was CorMedix Inc. incorporated?
CorMedix Inc. was founded in 2006 and is now based in Berkeley Heights, New Jersey.